Corbus Pharmaceuticals Holdings (CRBP) Common Equity (2013 - 2025)

Corbus Pharmaceuticals Holdings' Common Equity history runs 13 years deep, the most recent figure standing at $147.5 million for Q4 2025.

• On a quarterly basis, Common Equity rose 3.56% year-over-year to $147.5 million in Q4 2025; TTM through Dec 2025 was $147.5 million, a 3.56% increase from a year earlier, with the FY2025 full-year figure at $147.5 million, up 3.56% from the prior year.
• Common Equity grew to $147.5 million in Q4 2025 per CRBP's latest filing, from $92.1 million in the prior quarter.
• Across five years, Common Equity topped out at $150.5 million in Q3 2024 and bottomed at -$6.9 million in Q4 2023.
• The 5-year median for Common Equity is $77.3 million (2021), against an average of $75.7 million.
• Across the five-year window, Common Equity sank 120.93% in 2023 and soared 48136.54% in 2024, its largest moves.
• Year by year, Common Equity stood at $69.1 million in 2021, then plunged by 52.26% to $33.0 million in 2022, then plunged by 120.93% to -$6.9 million in 2023, then jumped by 2162.68% to $142.4 million in 2024, then grew by 3.56% to $147.5 million in 2025.
• Per Business Quant, the three latest CRBP Common Equity figures stand at $147.5 million (Q4 2025), $92.1 million (Q3 2025), and $111.0 million (Q2 2025).